logo
welcome
Reuters

Reuters

Lilly says weight loss drug cut heart failure risk by 38% in trial

Reuters
Summary
Nutrition label

78% Informative

Eli Lilly's weight loss drug Zepbound reduces risk of hospitalization, death and other outcomes for obese adults with a common type of heart failure.

The drug, also known as tirzepatide, reduced the risk of a composite of.

heart failure urgent visit or hospitalization by 38% compared to a placebo.

The condition accounts for nearly half of all heart failure cases.

VR Score

85

Informative language

89

Neutral language

73

Article tone

formal

Language

English

Language complexity

59

Offensive language

possibly offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links